Oncogenic pathway signatures in human cancers as a guide to targeted therapies - PubMed (original) (raw)
. 2006 Jan 19;439(7074):353-7.
doi: 10.1038/nature04296. Epub 2005 Nov 6.
Guang Yao, Jeffrey T Chang, Quanli Wang, Anil Potti, Dawn Chasse, Mary-Beth Joshi, David Harpole, Johnathan M Lancaster, Andrew Berchuck, John A Olson Jr, Jeffrey R Marks, Holly K Dressman, Mike West, Joseph R Nevins
Affiliations
- PMID: 16273092
- DOI: 10.1038/nature04296
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Andrea H Bild et al. Nature. 2006.
Abstract
The development of an oncogenic state is a complex process involving the accumulation of multiple independent mutations that lead to deregulation of cell signalling pathways central to the control of cell growth and cell fate. The ability to define cancer subtypes, recurrence of disease and response to specific therapies using DNA microarray-based gene expression signatures has been demonstrated in multiple studies. Various studies have also demonstrated the potential for using gene expression profiles for the analysis of oncogenic pathways. Here we show that gene expression signatures can be identified that reflect the activation status of several oncogenic pathways. When evaluated in several large collections of human cancers, these gene expression signatures identify patterns of pathway deregulation in tumours and clinically relevant associations with disease outcomes. Combining signature-based predictions across several pathways identifies coordinated patterns of pathway deregulation that distinguish between specific cancers and tumour subtypes. Clustering tumours based on pathway signatures further defines prognosis in respective patient subsets, demonstrating that patterns of oncogenic pathway deregulation underlie the development of the oncogenic phenotype and reflect the biology and outcome of specific cancers. Predictions of pathway deregulation in cancer cell lines are also shown to predict the sensitivity to therapeutic agents that target components of the pathway. Linking pathway deregulation with sensitivity to therapeutics that target components of the pathway provides an opportunity to make use of these oncogenic pathway signatures to guide the use of targeted therapeutics.
Comment in
- Cancer biology: signatures guide drug choice.
Downward J. Downward J. Nature. 2006 Jan 19;439(7074):274-5. doi: 10.1038/439274a. Nature. 2006. PMID: 16421553 No abstract available.
Similar articles
- Cancer biology: signatures guide drug choice.
Downward J. Downward J. Nature. 2006 Jan 19;439(7074):274-5. doi: 10.1038/439274a. Nature. 2006. PMID: 16421553 No abstract available. - "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management.
Glinsky GV. Glinsky GV. J Clin Oncol. 2008 Jun 10;26(17):2846-53. doi: 10.1200/JCO.2008.17.0266. J Clin Oncol. 2008. PMID: 18539963 Review. - An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.
Bild AH, Parker JS, Gustafson AM, Acharya CR, Hoadley KA, Anders C, Marcom PK, Carey LA, Potti A, Nevins JR, Perou CM. Bild AH, et al. Breast Cancer Res. 2009;11(4):R55. doi: 10.1186/bcr2344. Epub 2009 Jul 28. Breast Cancer Res. 2009. PMID: 19638211 Free PMC article. - Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.
Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee S, Barry WT, Dressman HK, Ginsburg GS, Marcom KP, Garman KS, Lyman GH, Nevins JR, Potti A. Acharya CR, et al. JAMA. 2008 Apr 2;299(13):1574-87. doi: 10.1001/jama.299.13.1574. JAMA. 2008. PMID: 18387932 Retracted. - Linking oncogenic pathways with therapeutic opportunities.
Bild AH, Potti A, Nevins JR. Bild AH, et al. Nat Rev Cancer. 2006 Sep;6(9):735-41. doi: 10.1038/nrc1976. Epub 2006 Aug 17. Nat Rev Cancer. 2006. PMID: 16915294 Review.
Cited by
- Insight into mammary gland development and tumor progression in an E2F5 conditional knockout mouse model.
To B, Broeker C, Jhan JR, Garcia-Lerena J, Vusich J, Rempel R, Rennhack JP, Hollern D, Jackson L, Judah D, Swiatnicki M, Bylett E, Kubiak R, Honeysett J, Nevins J, Andrechek E. To B, et al. Oncogene. 2024 Sep 28. doi: 10.1038/s41388-024-03172-4. Online ahead of print. Oncogene. 2024. PMID: 39341991 - Comprehensive analysis of consensus molecular subtypes for ovarian cancer from bulk to single-cell perspectives.
Zhao Z, Xing L, Cheng Q, Wu Z, Xue F, Peng Y, Zhang Y, Lv G, Zhang Y, Zhang C. Zhao Z, et al. J Biol Chem. 2024 Sep;300(9):107710. doi: 10.1016/j.jbc.2024.107710. Epub 2024 Aug 22. J Biol Chem. 2024. PMID: 39178946 Free PMC article. - Machine learning-based integration of CD8 T cell-related gene signatures for comprehensive prognostic assessment in lung adenocarcinoma.
Yong J, Wang D, Yu H. Yong J, et al. Transl Cancer Res. 2024 Jul 31;13(7):3217-3241. doi: 10.21037/tcr-23-2332. Epub 2024 Jul 17. Transl Cancer Res. 2024. PMID: 39145093 Free PMC article. - Machine learning-based integration develops an immunogenic cell death-derived lncRNA signature for predicting prognosis and immunotherapy response in lung adenocarcinoma.
Sun J, Guo H, Zhang S, Nie Y, Zhou S, Zeng Y, Sun Y. Sun J, et al. Sci Rep. 2024 May 22;14(1):11724. doi: 10.1038/s41598-024-62569-z. Sci Rep. 2024. PMID: 38778157 Free PMC article. - Pathway Activation Analysis for Pan-Cancer Personalized Characterization Based on Riemannian Manifold.
Li X, Hao J, Li J, Zhao Z, Shang X, Li M. Li X, et al. Int J Mol Sci. 2024 Apr 17;25(8):4411. doi: 10.3390/ijms25084411. Int J Mol Sci. 2024. PMID: 38673997 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources